Contusive spinal cord injury leads to a variety of disabilities owing to limited neuronal regeneration and functional plasticity. It is well established that an upregulation of glial-derived chondroitin sulphate proteoglycans (CSPGs) within the glial scar and perineuronal net creates a barrier to axonal regrowth and sprouting 1-5 . Protein tyrosine phosphatase s (PTPs), along with its sister phosphatase leukocyte common antigen-related (LAR) and the nogo receptors 1 and 3 (NgR), have recently been identified as receptors for the inhibitory glycosylated side chains of CSPGs 6-8 . Here we find in rats that PTPs has a critical role in converting growth cones into a dystrophic state by tightly stabilizing them within CSPG-rich substrates. We generated a membrane-permeable peptide mimetic of the PTPs wedge domain that binds to PTPs and relieves CSPG-mediated inhibition. Systemic delivery of this peptide over weeks restored substantial serotonergic innervation to the spinal cord below the level of injury and facilitated functional recovery of both locomotor and urinary systems. Our results add a new layer of understanding to the critical role of PTPs in mediating the growth-inhibited state of neurons due to CSPGs within the injured adult spinal cord.
blebs, resulting in a beaded axon with one tip or multiple side branches, all terminating in small punctate adhesive contacts ( Fig. 1c and Supplementary Video 3). This morphology is remarkably similar to that described in the early 20th century by Ramon y Cajal in the chronically injured cat spinal cord 11 . Interestingly, although PTPs is evenly distributed in a punctate pattern within motile axons and growth cones, it becomes concentrated in dystrophic stabilized growth cones ( Fig. 1d-i) . We found similar elevations of LAR, but not NgRs (Extended Data Fig. 1a, b ). In addition, we observed a large concentration of PTPs in the lesion penumbra after SCI (Extended Data Fig. 1c, d) . As PTPs co-localizes with adhesion plaques and focal adhesions 12, 13 , we hypothesized that it had a critical role in growth cone immobilization and progression into a dystrophic state. Therefore, we sought to target PTPs to relieve CSPG-mediated inhibition.
Upon analysing the structure of PTPs and related phosphatases, we identified a highly conserved 24-amino-acid intracellular wedge domain ( Fig. 2a and Extended Data Fig. 2a, b ). As wedge domains are known to regulate downstream signalling through a variety of mechanisms 7,14-16 , we designed intracellular sigma peptide (ISP), a novel peptide-mimetic of the PTPs wedge with a TAT domain to facilitate membrane penetration ( Fig. 2b) .
ISP was able to bind to recombinant human PTPs (Fig. 2c ). In rodent brain and spinal cord lysates, ISP pulled down both immature full-length PTPs and the mature functional complex ( Fig. 2d-f) 12 . In PTPs-null mice, only a very minor signal was detected, which may reflect nonspecific binding to PTPd, the third LAR family member ( Fig. 2d , e) 17 . No detectable binding was observed between ISP and other CSPG receptors such as LAR and NgRs (Extended Data Fig. 2e, f) . Interestingly, a LAR wedge-domain peptide (ILP) 14 was also capable of binding PTPs, but less efficiently than ISP (Fig. 2d, f and Extended Data Fig. 2c, d) .
We next asked whether ISP could release CSPG-mediated axonal inhibition in vitro. ISP treatment allowed adult sensory neurons to extend axons through a CSPG gradient in a dose-dependent manner to the same extent as pre-treatment with chondroitinase ABC (ChABC), which cleaves the glycosylated CSPG side chains and removes the PTPs ligand ( Fig. 2g -i) 6 . Time-lapse microscopy revealed that although growth cones treated with ISP were still transiently collapsed by CSPG, they continued to reform growth cones, allowing them to eventually cross the gradient ( Fig. 2k and Supplementary Video 4). Additionally, both ISP and ChABC treatments were sufficient to convert already stabilized dystrophic growth cones into a motile state (data not shown). Interestingly, human ISP and the wedge domain peptides of PTPd and LAR (IDP and ILP) demonstrated some efficacy, suggesting functional redundancy among LAR b β 3 
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family wedge domains. The wedge domain of PTPm (IMP), scrambled ISP, TAT alone, or ISP without TAT were ineffective ( Fig. 2h ).
Importantly, treatment of adult PTPs-null sensory neurons with ISP did not further increase crossings (Fig. 2j ) 6 . In addition, mature astrocytes, which have immunocytochemically undetectable PTPs 18 , were unable to traverse the CSPG gradient after ISP treatment (Extended Data Fig. 3a ). However, PTPs-expressing satellite glia were induced to cross successfully (Extended Data Fig. 3b ). These results suggest specificity of ISP interactions through PTPs.
ISP concentrations above the optimal dose for gradient crossing greatly reduced neuronal cell attachment, suggesting a reversal of the overadhered phenotype. ISP treatment decreased interactions between the CSPG-rich substrate and PTPs, allowing cells to detach in response to agitation ( Fig. 2l and Extended Data Fig. 3c, d ). This suggests that appropriate levels of adhesion are critical for regeneration across increasing concentrations of innately inhibitory CSPGs 19 .
The extracellular-signal-regulated kinase 1/2 (Erk1/2) cascade regulates a variety of processes, including axonal growth 20 . Erk1/2 phosphorylation was decreased in neuronal cells grown on a CSPG-rich substrate and both ISP and ChABC were able to restore the phosphorylation state of Erk1/2 to levels comparable to that on laminin-only substrates (Extended Data Fig. 4) 21 .
TAT-conjugated peptides are known to cross biological membranes, including the blood-brain barrier 22 . One hour after a single subcutaneous injection of fluorescein isothiocyanate (FITC)-conjugated ISP, we were able to visualize ISP in the intact nervous system (Extended Data Fig. 5a, b ). Therefore, we chose a non-invasive systemic treatment paradigm using daily subcutaneous injections, avoiding complications associated with intraparenchymal delivery 23 . Beginning 1 day after contusive SCI, rats were treated with ISP (11 mg per day), ILP (11 mg per day) or vehicle once daily for 7 consecutive weeks (Extended Data Fig. 5c-e ).
SCI disrupts connections between the bladder and brainstem micturition control centre, leading to reduced void frequency and an accompanying increase in void volume (Extended Data Fig. 6a , b) 24 . Twelve weeks after injury, ISP promoted a significant twofold increase in void frequency versus controls, along with a significant decrease in void volume ( Fig. 3a -c and Extended Data Fig. 6c -h). We used urodynamics to assess whether this improvement was a result of physiologically normal bladder activity. Rats urinate by contracting the detrusor muscle, resulting in a rapid increase in bladder pressure while the external urethral sphincter 
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(EUS) bursts phasically, expelling urine ( Fig. 3d ) 25 . No vehicle-or ILPtreated animals displayed multiple coordinated bursts of the EUS during a void ( Fig. 3e, h ). Although the detrusor was still hyperactive, 10 of the 15 analysed ISP-treated animals recovered coordination between bladder contractions and EUS phasic bursting, suggesting reconnection of a functional circuit ( Fig. 3f , g) 26 .
We measured locomotor recovery using the Basso, Beattie and Bresnahan (BBB) scale and a gridwalk test 27 . After SCI, vehicle-and ILPtreated animals recovered from hindlimb paralysis at day 1 to, on average, occasional weight bearing stepping at week 11 ( Fig. 3i ). ISP treatment resulted in a significant progressive recovery of locomotion, which began several weeks after injury ( Fig. 3i ). Thirty per cent of ISP-treated animals (versus zero vehicle/ILP-treated animals) demonstrated, at least, frequent coordinated stepping (BBB $ 13), with three rats achieving BBB scores $17.5 ( Fig. 3j-k ). Furthermore, ISP-treated animals made on average 58% fewer foot faults than control rats on the gridwalk test ( Fig. 3l, m ), suggesting recovery of sensorimotor coordination and balance. Importantly, aside from minor irritation at the injection site after multiple weeks of treatment, ISP did not induce neuropathic pain (Extended Data Fig. 7a, b ).
Interestingly, no correlation between ISP-induced recovered behaviours was observed (Extended Data Fig. 7c-e ). Using stringent threshold analyses, we determined that 21 of 26 ISP-treated animals recovered at least one behaviour, with 3 animals recovering all three ( Fig. 3n ). Further analyses demonstrated the degree to which responding animals benefited from treatment (Extended Data Fig. 7f -h). Taken together, this suggests that the re-acquisition of each behaviour is modular and not coincident, and may reflect anatomical differences in the pattern of axon re-innervation.
The behavioural results represent the average of five repetitions, each performed with newly synthesized peptide, blinded behavioural testers and a separate blinded treatment administrator. Although variability existed, ISP increased functional recovery of each behaviour in all cohorts (Extended Data Fig. 8 ). In a final group of animals, urinary, but not locomotor behaviours, responded to increasing concentrations of ISP, with our maximum (44 mg per day) dose improving urination markedly in all rats (Extended Data Fig. 7g ). Therefore, further optimization of the dose or administrative route of ISP may lead to additional functional improvements.
ISP treatment was not neuroprotective, as it did not lead to differences in lesion size or spared white matter ( Fig. 4a, b ). At the individual animal level, the variability in spared tissue correlated with functional recovery in vehicle-, but not ISP-treated rats (Extended Data Fig. 9 ).
Although regenerative pathways are difficult to examine after contusive SCI 28 , we did not observe any lengthy regenerating biotinylated dextran amine (BDA)-labelled corticospinal tract fibres (data not shown). We focused further analysis on the serotonergic system (5HT) neurons, which express LAR family receptors and contribute to proper neuromodulatory tone in locomotion and micturition circuitry 7, 26, 29, 30 . Contusive SCI led to a marked decrease in descending 5HT-positive fibres caudal to the lesion ( Fig. 4c , e, h). In animals exhibiting functional recovery after ISP treatment, we observed unusually shaped, densely sprouted territories of 5HT fibres below the level of the lesion ( Fig. 4d , f, i-n). These patterns corresponded in part with neurofilament staining (Extended Data Fig. 10 ), but were not present in sections stained for GFAP, ED1 or 49,6-diamidino-2-phenylindole (DAPI), ensuring that the sharp edges of staining were not due to tissue folds. We speculate that physical constraints of the perineuronal net may confine fibres in these patterns. Their spatial variability, in conjunction with differences in tract sparing from animal to animal after contusion, could partially account for the disparity in behavioural recovery between animals.
Treatment with the 5HT receptor antagonist methysergide at 14 weeks after SCI significantly reduced locomotor and urinary function in ISPtreated, but not vehicle-treated animals ( Fig. 4o, p) 26, 29 . This was most LETTER RESEARCH evident in ISP responders, animals that regained function beyond recovery thresholds. However, behavioural improvements were not fully reverted to vehicle levels and gridwalk scores were only minimally affected ( Fig. 4q ), suggesting plasticity of other pathways outside the serotonergic system.
While CSPGs have largely been thought to act as repulsive components of the extracellular matrix, our results suggest that regenerating adult growth cones can become permanently immobilized by CSPG gradients. These observations highlight an initial cellular mechanism regulated by PTPs that leads to the development of axonal dystrophy and the prevention of chronic regeneration and plasticity in vivo. Systemic modulation of PTPs opens a new therapeutic avenue in noninvasive treatments for enhancing functional recovery after a variety of injuries or diseases in which proteoglycans inhibit the attempt of axons to regenerate or sprout.
METHODS
In vitro DRG culture DRG and satellite glia dissociation and culture. DRGs were harvested as previously described 9 . Briefly, DRGs were dissected from adult female Sprague-Dawley rats (Harlan) and incubated in a solution of collagenase II (200 U ml 21 , Worthington Biochemical Corporation) and dispase II (2.5 U ml 21 , Roche Diagnostics) in Ca 21 /Mg 21 free Hank's balanced salt solution (HBSS-CMF, Invitrogen). Cells were centrifuged at 1,000-2,000 r.p.m., washed and gently triturated in HBSS-CMF three times. Dissociated DRGs were then resuspended in Neurobasal-A media supplemented with B-27, Glutamax, and penicillin/streptomycin (Invitrogen). DRGs were plated in Delta-T dishes (Fisher) at a density of 800 cells cm 22 or on coverslips at a density of 1,000 cells cm 22 . Dish preparation and time-lapse microscopy. Delta-T-cell culture dishes were prepared as previously described 31 . Culture dishes were rinsed with sterile water and then coated with poly-L-lysine (0.1 mg ml 21 , Sigma-Aldrich) overnight at room temperature, rinsed with sterile water, and allowed to dry. Aggrecan spot gradients were formed by allowing 2 ml of aggrecan solution (2 mg ml 21 in HBSS-CMF, Sigma-Aldrich) to dry onto the culture surface. The surface of the dish was bathed in laminin solution (10 mg ml 21 in HBSS-CMF, Invitrogen) for 3 h at 37 uC. The laminin bath was subsequently removed and cells were plated without allowing the surface of the dish to dry. For conditions with laminin alone, the aggrecan spots were excluded from the protocol.
Prior to time-lapse imaging, adult neurons were incubated at 37 uC for 4-6 days in Neurobasal-A media with either vehicle (water) or 2.5 mM peptide. Neurobasal-A media with HEPES (50 mM, Sigma-Aldrich) and either vehicle or 2.5 mM peptide was added to the cultures before imaging in a heated stage apparatus. Time-lapse images were acquired every 30 s for at least 1.5 h with a Zeiss Axiovert 405M microscope using a heated 3100 oil-immersion objective. Growth cones that extended normal to the spot rim were chosen for analysis. We tracked and charted the behaviour of growth cones in our in vitro assay with Metamorph software. n 5 19 laminin, 24 control, 24 ISP, 26 ISP. For delayed treatment, n 5 14 ISP and ChABC. PTPs concentration quantification. High-magnification images of PTPs expression (R&D Systems, 1:100) in growth cones, either motile on uniform substrates of laminin (5 mg ml 21 ) or dystrophic within the CSPG gradient were analysed with ImageJ. Both the growth cone and axon were manually traced and the mean pixel intensity was calculated. All images were taken using identical settings. CSPG gradient crossing assay. CSPG gradients were prepared as described previously 9 . Glass coverslips (1.6 mm, Fisher Scientific) coated with poly-L-lysine and nitrocellulose were spotted with a 2 ml solution of aggrecan (0.7 mg ml 21 ) and laminin (5 mg ml 21 ) in HBSS-CMF (4 spots per coverslip). After the spots were allowed to dry, the coverslips were incubated with laminin (5 mg ml 21 ) in HBSS-CMF at 37 uC for 3 h. Dissociated DRG neurons were plated at a density of 1,000 cells cm 22 in Neurobasal-A supplemented with B27, Glutamax and penicillin/streptomycin and incubated for 5 days at 37 uC. For peptide experiments, appropriate concentrations of peptide were added to the media at the time of plating. For ChABC experiments, 0.1 U ml 21 ChABC (Seikagaku) was added to coverslips for 2 h after the laminin bath before cell plating.
At 5 days, cultures were fixed in 4% paraformaldehyde in PBS for 30 min. After several rinses in PBS, the coverslips were incubated in blocking solution (5% normal goat serum or normal donkey serum, 0.1% BSA, and with or without 0.1% Triton X-100 in PBS) for 1 h at room temperature and then incubated overnight at 4 uC in primary antibody. Anti-bIII-tubulin (1:500; Sigma-Aldrich), anti-CS56 (1:500; Sigma-Aldrich), anti-PTPs (1:100, R&D systems), anti-GFP (1:500, Invitrogen), anti-S100 (1:1,000, Sigma-Aldrich), anti-GFAP (1:5,000, DAKO), anti-NgR (1:100, Millipore) and anti-LAR (1:100, Santa Cruz) were used as primary antibodies. Coverslips were rinsed several times in PBS and then incubated in the appropriate secondary antibody (Molecular Probes) overnight at 4 uC. Coverslips were rinsed with PBS again, and mounted on glass slides in Citifluor (Ted Pella) mounting medium. Specimens were examined using a Leitz Orthoplan 2 fluorescence microscope. Wedge identification. The intracellular domains of rat PTPs (Protein Data Bank (PDB) accession 2FH7) and human LAR (PDB accession 1RPM) were visualized using UCSF Chimera 1.6.1. The wedge domains of human, rat and mouse PTPs and PTPd were identified by BLAST alignment with the known wedge domain of LAR 14 . Peptide preparation. Peptides were synthesized commercially with C-terminal amidation (Genscript), and purity was assessed as .98% by mass spectrometry. Lyophilized peptides were dissolved in sterile water and stored at 280uC until use. Peptide sequences are as follows: ISP, NH 2 -GRKKRRQRRRCDMAEHMERLKA NDSLKLSQEYESI-NH 2 ; human ISP, NH 2 -GRKKRRQRRRCDMAEHTERLKA NDSLKLSQEYESI-NH 2 ; ISP no TAT, NH 2 -DMAEHMERLKANDSLKLSQEYESI-NH 2 ; ILP, NH2-GRKKRRQRRRCDLADNIERLKANDGLKFSQEYESI-NH 2 ; IDP, NH 2 -GRKKRRQRRRCELADHIERLKANDNLKFSQEYESI-NH 2 ; IMP, NH 2 -DL LQHITQMKCAEGYGFKEEYESGRKKRRQRRRC-NH 2 ; scrambled ISP, NH 2 -G RKKRRQRRRCIREDDSLMLYALAQEKKESNMHES-NH 2 ; TAT, NH 2 -GRKKR RQRRRC-NH 2 . Quantification. All quantification was done blind. The number of bIII-tubulinpositive axons crossing the CSPG gradient (visualized using the CS56 antigen) was counted and divided by the total number of neuronal cell bodies contained within each gradient. Each gradient was counted as an individual data point. n 5 112 control, 43 ChABC, 20 scrambled ISP, 57 ILP, 18 human ISP, 18 IDP, 16 IMP, 16 ISP  no TAT, 16 TAT. For ISP, n (mm) 5 16 (10), 16 (5) , 34 (2.5), 49 (1.25), 27 (0.625, 0.25, 0.025, 0.0025).
For analysis of PTPs concentration, PTPs-stained neuronal growth cones and axons either entering the gradient or growing on uniform laminin were manually traced using ImageJ and the average pixel intensity was calculated. Astrocyte preparation. Astrocytes were harvested from postnatal day 0/1 (P0/1) rat cortex as previously described 31 . Cortices were finely minced and treated with 0.5% trypsin in EDTA. Cells were plated in DMEM/F12 (Invitrogen) with 10% FBS (Sigma-Aldrich) and 2 mM Glutamax on T75 flasks coated with poly-L-lysine and shaken to remove non-adherent cells. Astrocytes were allowed to mature in culture for at least 4 weeks, and used within 2 weeks of maturity. Astrocytes were harvested with trypsin and plated at a density of 12,500 cells cm 22 . Adhesion assay. Poly-L-lysine-coated glass coverslips were uniformly coated with a mixture of aggrecan (25 mg ml 21 ) and laminin (1 mg ml 21 ) for 3 h at 37 uC. DRG neurons were plated on coverslips (as described earlier) and incubated for 5 days at 37 uC. Cultures were then removed from the incubator and placed on a rotary shaker for 15 min at 80 r.p.m. Control coverslips were removed from the incubator, but not placed on the shaker. After shaking, the supernatants were immediately collected, centrifuged, re-suspended in 20 ml Neurobasal-A media, and placed on ice. The number of neurons released from each coverslip was counted with a haemocytometer. Coverslips were carefully fixed with 4% paraformaldehyde and stained for bIII-tubulin to visualize remaining neurons and axons (as described earlier). n 5 28 control and ILP, 16 ISP. DNA constructs and electroporation. mPTPs in pECFP-N1 was a gift from A. M. Craig. Full-length mouse PTPs with four fibronectin domains (BC052462) was subcloned into pEF1a-AcGFP1-N1 (Clontech) between NheI and HindIII. pEF1a-mPTPs-AcGFP1-N1 was electroporated into adult DRG neurons with the Amaxa Rat Neuron Nucleofector Kit (Lonza) using the manufacturer's instructions. PTPs pulldown Biotinylated peptide pulldown. For pulldown experiments, we used the Pierce Pull-Down Biotinylated Protein:Protein Interaction Kit (Thermo Scientific 21115). 100 mg ml 21 of biotinylated-peptide (Genscript) was incubated overnight on an orbital shaker at 4 uC with streptavidin beads. After incubation, extra biotin was added and allowed to incubate overnight to ensure the binding of all streptavidin. After three washes with TBS, either recombinant GST-tagged PTPs ICD (D1/D2 500 ng, Sigma, D1 500 ng, Abcam), spinal cord lysate from either wild-type or PTPs-null mice, or brain lysate from an adult female Sprague-Dawley rat. Neural tissue was quickly extracted and flash frozen with liquid nitrogen. The tissue was homogenized in tissue homogenization buffer (20 mM Tris, 0.5 mM EDTA, 0.5 mM EGTA and 8% sucrose, pH 7.4) and 1:500 protease inhibitor cocktail (Abcam) on ice. The lysate was centrifuged at 13,000 r.p.m. for 20 min before addition to the beads. One-hundred and fifty microlitres of each lysate was added to the beads and allowed to incubate overnight at 4 uC. After three washes, beads were incubated with elution buffer for 10 min at room temperature. Beads were then centrifuged at 12,000 r.p.m. to collect eluted lysate. SDS-PAGE and western blot. Thirty microlitres of the pulldown material with 43 Laemmli Buffer was boiled for 10 min at 100 uC and loaded into 7.5% TBX Mini-Protean Gels (Bio-Rad 456-1029) with Bio-Rad Precision Plus Protein Standard (Bio Rad 161-0374). The gel was run for about 1.5 h at 100 V in 13 Tris Glycine SDS Buffer. Gels were stained with Sypro Ruby Red (Sigma-Aldrich) to visualize proteins within the gel. Transfer occurred overnight at 15 V using a PVDF membrane. We blocked at least 2 h in 5% milk powder, 0.1% Tween-20 before overnight incubation with an antibody against GST (Cell Signaling), PTPs ICD (1:100, Abnova), PTPs ECD (1:1,000, Abcam), anti-NgR (1:500, Millipore) or anti-LAR (1:1,000, R&D Systems). We washed five times for 5 min in 13 PBS-0.1% Tween-20 before blocking overnight with a horseradish peroxidase (HRP)-conjugated secondary (1:1,000) . The blot was developed using a chemiluminescence substrate (Thermo Sci) after five times five 13 PBS/0.1% Tween-20 washes. All experiments were repeated .3 times. CSPG signalling Plating SH-SY5Y cells on laminin and CSPG substrates. The SH-SY5Y neuronal cell line (ATCC) was grown in Hyclone Dulbecco's modified Eagle's highglucose media (GE Healthcare Life Sciences, SH-30081.02) supplemented with 4 mM L-glutamine, 1 mM sodium pyruvate, 1% penicillin/streptomycin/neomycin (PSN) and 10% heat-inactivated fetal bovine serum (Invitrogen). SH-SY5Y cells were plated at an initial density of 12,000 cells cm 22 onto tissue culture surfaces for LETTER RESEARCH 4 days under different conditions, including (1) laminin, (2) laminin plus CSPG, (3) laminin plus CSPGs pre-treated with ChABC, (4) laminin plus ISP in the media, (5) laminin plus CSPG plus ISP in the media. Tissue culture dishes were coated with laminin (2 mg ml 21 , Sigma, L2020) and/or CSPG (15 mg ml 21 , Millipore, cc117) for 3 h at room temperature. Of note, CSPGs used in this study contained a mixture of neurocan, phosphacan, versican and aggrecan. Where appropriate, ChABC (0.1 U ml 21 , Sigma, C3667-10UN) was added with laminin plus CSPG mixture to tissue culture surfaces for 1 h and incubated at 37 uC during coating and before cell plating. In the ISP condition, cells were pre-treated with ISP (2.5 mM) for 30 min. Immunoblotting. Cells were harvested from culture plates 4 days after cell plating and homogenized in RIPA buffer (Thermo Fisher) containing SigmaFast Protease Inhibitor (Sigma). A total of 30-50 mg protein was loaded into the gel and then transferred to a nitrocellulose membrane (Bio-Rad). The membranes were then blocked in 5% non-fat milk in Tween Tris buffered saline (TBST) for 1 h and incubated overnight at 4 uC with P-p44/42 MAPK (Cell Signaling, Rabbit 1:500) diluted in the blocking solution. The membranes were washed and incubated with HRPconjugated goat anti-rabbit antibodies (1:4,000, Biorad). Membranes were then incubated in ECL plus immunoblotting detection reagents (Thermo Scientific Pierce) according to the manufacturer's specifications. Blots were then stripped of their primary and secondary antibodies for 30 min in 0.2 M NaOH and re-probed with primary antibody p44/42 MAPK (Erk1/2) (Cell Signaling, Rabbit 1:1,000) overnight followed by incubation with secondary antibody and ECL. Quantification. Immunoreactive bands were quantified using AlphaEaseFC (Fluor-Chem, 8900). The ratio of phosphorylated (p)Erk1/2 to total (t)Erk1/2 for each condition was calculated. Data are reported as means 6 s.e.m., and P # 0.05 was considered significant. Statistical analyses of intensity measurements were tested by one-way ANOVA comparing conditions followed by post-hoc pairwise multiple-comparison testing by the Holm-Sidak method. Animals and contusive SCI Animals. Adult female Sprague-Dawley rats (225-250 g) were obtained from Harlan. All procedures were approved by the Institutional Animal Care and Use Committees. PTPs-null mice were provided by M. Tremblay. All PTPs-null experiments were performed in collaboration with Y. Shen. Contusive SCI. Briefly, adult female Sprague-Dawley rats (230-250 g) were obtained from Harlan and acclimated to the animal resource centre, behaviour analysis chambers and handlers. Rats were injected intraperitoneally with ketamine (60 mg kg 21 ) and xylazine (10 mg kg 21 ). The musculature was cut from T7-T9 and the dorsal surface of T8 was exposed by laminectomy. The vertebral column was stabilized by clamping the T7 and T9 vertebral bodies with forceps fixed to the base of an Infinite Horizon Impact Device. The animals were situated on the platform, and the 2.5 mm stainless steel impactor tip was positioned over the midpoint of T8 and impacted with 250 kdyn force. The overlying musculature was closed using suture, the skin was closed using wound clips and the animals were treated with Marcaine at the incision site. The force/displacement graph was used to monitor impact consistency and any animals that exhibited an abnormal impact graph or greater than 10% deviation from 250 kdyn were immediately excluded from the study.
After surgery, pain was monitored and animals were treated with intramuscular buprenorphine at signs of discomfort. In addition, manual bladder expression was performed 2-3 times daily for 2-3 weeks until a voiding reflex returned and animals could leak urine. Five vehicle animals and two ILP animals were removed from the study and euthanized due to bladder infections and other serious ailments. One ISP-treated animal was removed due to a bladder stone. Dorsal column crush injury. Dorsal column crush was performed similarly to as described previously 31 . Rats were anaesthetized with inhaled isoflurane gas (2%) for all surgical procedures. A T1 laminectomy was performed to expose the dorsal aspect of the C8 spinal cord segment. Durotomies were made bilaterally 0.75 mm from midline with a 30-gauge needle. A dorsal column crush lesion was then made by inserting Dumont no. 3 jeweller's forceps into the dorsal spinal cord at C8 to a depth of 1.0 mm and squeezing the forceps, holding pressure for 10 s and repeating two additional times. The muscle layers were sutured with 4-0 nylon suture, and the skin was closed with surgical staples. Animals were perfused at 14 days after injury. Systemic peptide treatment. All randomization and peptide treatments were prepared by a blinded laboratory member not associated with behavioural analyses. First, a vehicle solution of 1.25 ml DMSO in 23.75 ml sterile saline was prepared for each animal. Next, appropriate peptide was added to each of the vehicle solutions where applicable so that the final peptide concentration of each solution was 5 mM. Each drug solution was then aliquotted into 50 individual 1.5 ml Eppendorf tubes, each corresponding to a single animal's daily dose, and frozen at 220 uC. All peptides were randomized and blinded to both the animal treatment administrator and separate behavioural analyser. At 24 h after SCI and each morning thereafter for 49 consecutive days, animals were given a 500 ml subcutaneous injection of the appropriate blinded treatment into the back above the lesion (n 5 21 vehicle, n 5 26 ISP, n 5 10 ILP) This experiment was carried out with five different cohorts of animals, with freshly synthesized peptide validated in vitro using the CSPG gradient assay and prepared for each cohort of animals. ILP treatments were only performed in the first and last cohort because we did not observe behavioural improvement with ILP treatment.
For the dose response, additional injured animals (N 5 5 per group, cohort 4) were injected with 1/33 ISP (3.6 mg per day), 1/23 ISP (5.5 mg per day), 23 ISP (22 mg per day), 33 ISP (33 mg per day) or 43 ISP (44 mg per day). FITC-ISP peptide tracking. FITC-ISP was synthesized by Genscript with FITC conjugated to the N-terminus TAT domain. A single 500 ml injection of either 10 mM FITC-ISP in 5% DMSO plus saline or vehicle was given to animals subcutaneously into the back. At 1 h after injection, spinal cords were immediately removed and snap frozen. Twenty-micrometre-thick coronal sections of unfixed spinal cord tissue were collected on a cryostat and immediately imaged on a Leitz Orthoplan 2 fluorescence microscope. Methysergide. A subset of ISP-and vehicle-treated animals were injected with methysergide (5 mg kg 21 , Sigma-Aldrich) intraperitoneally once a day for 3 days at 14 weeks after SCI (n 5 8 vehicle, n 5 12 ISP). Gridwalk and metabolic cage analyses were performed on days 0 and day 3, while BBB scoring was conducted daily. In addition to the full population, the animals whose behaviour started above or below a threshold level of two standard deviations above vehicle mean (see Fig. 4f ) were plotted separately as responding and non-responding. Behavioural analysis Open field BBB. All behaviour analyses were conducted by two blinded observers separate from the researcher performing the daily dosing. Each animal was tested on days 1, 4, 7 and weekly thereafter until week 11. Animals were allowed to freely roam on an open field while being observed by two Ohio State Spinal Cord Injury Course expertly trained observers and scored according to the BBB guidelines 27 . Any animal with a BBB score of greater than 1 at day 1 was removed from the study. Data were quantified as the average of the two hind limbs, compiled, and graphed. Gridwalk. The gridwalk test was performed at 12 weeks after SCI. Animals were allowed to freely roam on a 75 cm 3 40 cm raised grid (2.5 mm thick wires, 2 cm gaps between wires) for 5 min while their progress was tracked with an overhead camera and quantified as total distance travelled (Ethovision). Foot faults were counted manually by a blinded observer and quantified as total number of hindlimb faults per metre. Thermal hyperalgesia. Hyperalgesia analysis was performed at 12 weeks after injury by a blinded observer as published previously 32 . Animals were given 30 min to acclimate to the plexiglass cage before testing (Ugo Basile). The infrared radiation source (intensity 5 58) was carefully placed under each hindpaw. Time to withdrawal was recorded as an average of five trials on each paw, with the longest and shortest time removed. Mechanical allodynia. The Von Frey hair protocol for the hind paw was adapted from the Ohio State University Spinal Cord Injury Program. Briefly, animals satisfying the weight-bearing criteria were acclimated to the Von Frey testing boxes for at least 15 min. A total of ten trials were performed starting with the 5.18 monofilament while animals were distracted with a treat. The monofilament was tested on the plantar surface of the centre of the paw between the foot pads. A positive response was recorded if an animal withdrew its paw when the monofilament was presented. At least 30 s elapsed between each trial for the same hind paw. Positive responses led us to test with progressively smaller monofilaments. Conversely, negative responses led us to test with progressively larger monofilaments until monofilament 6.10. The threshold value was defined as the lowest monofilament level at which 50% or more of the trials resulted in a positive withdrawal. Metabolic cage micturition analysis. At 6 weeks and 12 weeks after SCI, animals were placed in a metabolic cage (Braintree Scientific) for measurement of voiding patterns. The voided urine was measured continuously via a force transducer/strain gauge (Grass Technologies) and plotted in Spike2 (Cambridge Electrical Design, sampled at 20 Hz). Animals were kept in this cage for 16 h with ample water and food during the period of urine collection and measurement. The criteria for the micturition pattern analysis included void frequency (voids per h) and the void volume (ml per void). The total volume of expelled urine was not included because of variations in water intake between individual animals. n 5 11 naive animals. Urodynamics. Terminal urodynamic recordings were performed similarly to as described previously 33 . Briefly, rats were anaesthetized at 14 weeks after SCI with 0.8 g kg 21 urethane delivered subcutaneously. A polyethylene-50 catheter was carefully inserted through the urethra into the bladder for delivery of saline. Fine wire electrodes (76.2 mm) (0.00399diameter Teflon-insulated silver wire, A-M Systems) were inserted percutaneously via the vagina on both sides of the urethra to monitor the EUS electromyography (EMG) activity. The electrodes were connected to a preamplifier (HZP; Grass-Technologies), which was connected to an amplifier (Grass-Technologies) with low-and high-pass frequency filters at 30 Hz and 3 kHz, respectively, and signal was sampled at a rate of 10 kHz (Power 1401, Spike2; Cambridge Electronic Design). Continuous cystometrograms (CMGs) were collected using constant infusion (6 ml h 21 ) of room temperature saline (Aladdin-1000 single syringe infusion pump; World Precision Instruments) through the catheter into the bladder to elicit repetitive voids. The bladder pressure was recorded via the same catheter used for saline infusion, using a pressure transducer (GrassTechnologies) connected to the recording system and sampled at a frequency of 2 kHz. Animals that received methysergide did not receive urodynamic analysis. n 5 11 vehicle, 15 ISP, 6 ILP. Immunocytochemistry and tracing Perfusion and sectioning. To obtain spinal cord sections, rats were transcardially perfused with ice-cold 4% paraformaldehyde in PBS, and the spinal cords were dissected out. After the tissue was postfixed in 4% paraformaldehyde overnight at 4 uC and cryoprotected with 30% sucrose, spinal cords were frozen in OCT mounting media and sectioned on a Hacker cryostat at a thickness of 20 mm. Immunocytochemistry. Mounted sections were washed three times with PBS followed by blocking in 5% normal goat serum (NGS) and 0.1% bovine serum albumin (BSA) in PBS. 0.1% Triton X-100 was added to the blocking buffer depending on the antigen used. After blocking, sections were incubated in primary antibody diluted in blocking buffer overnight at 4 uC. Primary antibodies used were mouse anti-NeuN (1:100, Chemicon), anti-GFAP (1:1,000, Dako), mouse anti-ED1 (Chemicon, 1:100) rabbit anti-5-HT (1:500, Immunostar), and anti-neurofilament (1:500, Sigma-Aldrich). For in vivo PTPs staining, sagittal 20 mM sections encompassing regions both rostral and caudal to the lesion were probed with anti-PTPs antibody (1:500, Abnova). The next day, the sections were washed extensively with PBS and incubated in the appropriate secondary antibody or avidin substrate conjugated to AlexaFluor 488, 594 or 633 (1:500, Molecular Probes) overnight. After extensive washing, the sections were stained with DAPI (1:1,500 in PBS, Sigma-Aldrich), washed, coverslipped and viewed with a confocal microscope (Zeiss, Germany). Pixel intensity was measured on images taken on a standard fluorescent microscope (Leica) with a uniform exposure setting and analysed using ImageJ. White matter analysis. Spared white matter analysis was conducted by EC staining as previously published 34 . Briefly, room temperature 20 mm sections were placed in fresh acetone for 10 min, removed and allowed to dry for 30 min. Sections were stained with freshly filtered EC solution (Sigma-Aldrich) for 30 min and washed in running tap water for 5 min. The stain was differentiated in 5% ferric ammonium sulphate (Sigma-Aldrich) for 15 min and again washed with running tap water for 5 min. The differentiation was completed with borax-ferricyanide solution (Sigma-Aldrich) for 10 min, briefly washed with running tap water and allowed to dry. Slides were dehydrated in 70%, 95% and 100% ethanol for 2 min each followed by xylene for 2 min. Slides were coverslipped with a VectaMount Permanent Mounting Medium (Vector Laboratories). n 5 10 vehicle, 14 ISP. Lesion volume. Spinal cord sections stained with GFAP were analysed for lesion volume. After staining, sections were digitalized with a Leica SCN 400 Slide Scanner. Fifteen 20 mm coronal sections (one of every ten serial sections was stained, 200 mm between sections) both rostral and caudal of lesion epicentre were analysed for a total of 6 mm of spinal tissue. Sections were traced in ImageJ for volume calculation. n 5 9 vehicle, 14 ISP. 5HT analyses. Coronal sections of lumbar spinal cord were analysed for 5HT intensity. The staining and imaging settings were uniform for all images. High exposure settings were used to maximize the signal to noise ratio, allowing for large patterns of 5HT expression to be visualized. ImageJ threshold analysis was used to eliminate all background from each section, leaving only the patterns of 5HT expression. The area of innervation and per cent coverage of the grey matter was identified by analysing all particles in the grey matter at threshold intensity. Eight 20 mm sections, (corresponding to 1.6 mm of lumbar tissue) were analysed in ImageJ and averaged, with the highest and lowest intensity removed. n 5 13 vehicle, 18 ISP. Tracing. Cortical spinal tract labelling was performed as published previously 35 . Ten per cent BDA (Molecular Probes) was injected into 16 locations in the rat motor cortex at 12 weeks after injury. Animals were killed 2 weeks after labelling. BDA labelling was visualized using an avidin-biotin peroxidase incubation followed by diaminobenzidine and H 2 O 2 (Vector Labs). Statistical analysis. All statistical analyses were performed using Graphpad Prism. All results are presented as mean 1 s.e.m. Sample sizes were initially determined using statistical software to calculate the minimum total required number of animals or assays. All reported groups are above the minimum calculated sample size. In vitro. For PTPs intensity measurements, gradient crossings and adhesion assays, all statistical analysis was performed with one-way ANOVA between all groups in each individual experiment. In vivo. For void frequency, void volume and gridwalk data sets, D'Agostino-Pearson and Shapiro-Wilk tests were first performed to determine if any individual data set abided to a normal, Gaussian distribution. Naive, vehicle control and ILP all passed the normality test, while ISP failed in all. Next, we performed ROUT analysis to identify outliers. No values were excluded from analysis, although a single ILP void frequency data point was identified as an outlier. Statistical analysis on these behaviours was performed with a one-way ANOVA and post-hoc Kruskal-Wallis test.
For BBB, we performed a repeated measures two-way ANOVA to compare vehicle, ILP and ISP. No normality tests were performed because BBB is a nonlinear scale. Post-hoc analysis at individual time point was performed with Tukey's test.
After methysergide treatment, BBB analysis was performed with repeated measures two-way ANOVA. For both gridwalk and void frequency, we compared premethysergide to post-methysergide treatment with a two-way ANOVA. The analysis between responding and non-responding animals was performed separately. Anatomy. 5HT area and per cent grey matter coverage, the average value over the eight lumbar sections of ISP and vehicle control were compared with a Student's t-test. Regression analysis. Regression analysis was performed by creation of a matrix of behavioural and anatomical scores for each animal. A separate matrix was created for vehicle and ISP treatment. Regression values (r) were identified by comparing two individual variables. The Pearson or Spearman coefficients were identified for parametric and non-parametric data sets, respectively. 
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